This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

DexCom, Abbott withdrew their patent disputes at UPC

( January 24, 2025, 15:19 GMT | Official Statement) -- MLex Summary: Companies DexCom and Abbott withdrew all claims and counterclaims including revocation actions in their disputes at the Unified Patent Court concerning European patents 3,831,282 and 3,435,866. The UPC Court of Appeal allowed the withdrawals, making the initial decisions on patent revocations void and restoring the patent's validity. The court declared the proceedings closed, and ordered a 60 percent reimbursement of court fees to DexCom. The decisions are attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections